BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20339441)

  • 1. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP.
    Koehrer S; Keating MJ; Wierda WG
    Leukemia; 2010 May; 24(5):1096-8. PubMed ID: 20339441
    [No Abstract]   [Full Text] [Related]  

  • 2. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia.
    Jolliffe E; Romeril K
    Intern Med J; 2014 Jul; 44(7):697-9. PubMed ID: 25041772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag for chronic immune thrombocytopenia.
    Milosevic I; Slade E; Drysdale H;
    Lancet; 2016 Jan; 387(10016):336. PubMed ID: 26842445
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag for chronic immune thrombocytopenia - Authors' reply.
    Grainger JD;
    Lancet; 2016 Jan; 387(10016):336-337. PubMed ID: 26842444
    [No Abstract]   [Full Text] [Related]  

  • 7. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.
    Piccin A; Amaddii G; Natolino F; Billio A; Cortelazzo S
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s149-50. PubMed ID: 23736912
    [No Abstract]   [Full Text] [Related]  

  • 8. Sustaining platelet counts in chronic ITP.
    Nurden AT
    Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
    [No Abstract]   [Full Text] [Related]  

  • 9. Eltrombopag in thrombocytopenia.
    Zimmer J; Hentges F; Andrès E
    N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
    [No Abstract]   [Full Text] [Related]  

  • 10. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
    Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
    Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is publication? The case of eltrombopag.
    Benham L; Guo L; Turner R
    Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
    [No Abstract]   [Full Text] [Related]  

  • 12. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
    Zhang Y; Kolesar JM
    Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
    González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
    Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
    [No Abstract]   [Full Text] [Related]  

  • 14. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
    Gudbrandsdottir S; Frederiksen H; Hasselbalch H
    Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Thrombopoietin-Receptor Agonist in CVID-Associated Immune Thrombocytopenia.
    Carrabba M; Barcellini W; Fabio G
    J Clin Immunol; 2016 Jul; 36(5):434-6. PubMed ID: 27072856
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombopoietin-receptor agonists in children with immune thrombocytopenia.
    Neunert CE; Grace RF
    Lancet; 2015 Oct; 386(10004):1606-9. PubMed ID: 26231462
    [No Abstract]   [Full Text] [Related]  

  • 18. Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
    Ferretti A; Baldacci E; Miulli E; Canichella M; Di Rocco A; Pulsoni A; Martelli M; Serrao A; Chistolini A; Gabriella Mazzucconi M; Foà R; Santoro C
    Br J Haematol; 2019 Sep; 186(6):e217-e219. PubMed ID: 31364154
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune thrombocytopenic purpura--from agony to agonist.
    Schwartz RS
    N Engl J Med; 2007 Nov; 357(22):2299-301. PubMed ID: 18046034
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.